{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:35:50Z","timestamp":1789706150793,"version":"4.0.1"},"reference-count":17,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.3892\/or.2015.4314","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T03:45:55Z","timestamp":1443411955000},"page":"2864-2870","source":"Crossref","is-referenced-by-count":21,"title":["Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells"],"prefix":"10.3892","volume":"34","author":[{"given":"RIKI","family":"OKITA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KATSUHIKO","family":"SHIMIZU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUJI","family":"NOJIMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKURO","family":"YUKAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AI","family":"MAEDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHINSUKE","family":"SAISHO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASAO","family":"NAKATA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,9,28]]},"reference":[{"key":"key20180107212703_b1-or-34-06-2864","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0003-4975(99)01038-3","article-title":"Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically","volume":"68","author":"Rusch","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"key20180107212703_b2-or-34-06-2864","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107212703_b3-or-34-06-2864","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"key20180107212703_b4-or-34-06-2864","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107212703_b5-or-34-06-2864","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Cancer and Leukemia Group B (CALGB 30101): Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107212703_b6-or-34-06-2864","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"},{"key":"key20180107212703_b7-or-34-06-2864","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/ijc.25896","article-title":"Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR-and HER2-overexpressing esophageal cancer cell lines","volume":"129","author":"Mimura","year":"2011","journal-title":"Int J Cancer"},{"key":"key20180107212703_b8-or-34-06-2864","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10120-012-0219-5","article-title":"Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity","volume":"16","author":"Shiraishi","year":"2013","journal-title":"Gastric Cancer"},{"key":"key20180107212703_b9-or-34-06-2864","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","article-title":"Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients","volume":"97","author":"Usami","year":"2006","journal-title":"Cancer Sci"},{"key":"key20180107212703_b10-or-34-06-2864","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"key20180107212703_b11-or-34-06-2864","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"key20180107212703_b12-or-34-06-2864","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107212703_b13-or-34-06-2864","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/0008-5472.CAN-07-2404","article-title":"Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib","volume":"68","author":"Gilmer","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107212703_b14-or-34-06-2864","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"key20180107212703_b15-or-34-06-2864","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107212703_b16-or-34-06-2864","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3892\/ijo.2012.1607","article-title":"Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma","volume":"41","author":"Kurai","year":"2012","journal-title":"Int J Oncol"},{"key":"key20180107212703_b17-or-34-06-2864","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clbc.2014.11.004","article-title":"A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer","volume":"15","author":"Rimawi","year":"2015","journal-title":"Clin Breast Cancer"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4314\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T16:27:14Z","timestamp":1515342434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,28]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,9,28]]},"published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.3892\/or.2015.4314"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4314","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,28]]}}}